Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Cladribine and Cyclophosphamide Lymphodepletion Prior to Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 4884.

https://doi.org/10.1182/blood-2023-187078

Published: 2023

Journal Articles

Poor Hematopoietic Reserve at the Time of CD19 CAR T-Cell Infusion Is Associated with Long Term B-Cell Aplasia

Blood (2023) 142 (Supplement 1): 3512.

https://doi.org/10.1182/blood-2023-185097

Published: 2023

Journal Articles

Impact of Sarcopenia and Subsequent Muscle Loss on Post-CAR T-Cell Outcomes in Relapsed/Refractory Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 2130.

https://doi.org/10.1182/blood-2023-187294

Published: 2023

Journal Articles

A Novel Composite Endpoint of Toxicity-Free, Progression-Free Survival (TPFS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1776.

https://doi.org/10.1182/blood-2023-185117

Published: 2023

Journal Articles

Cladribine and Cyclophosphamide Lymphodepletion Prior to Brexucabtagene Autoleucel in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma

Filip Ionescu, Rawan Faramand, Hanna Bailey, Christina A Bachmeier, Elizabeth DiMaggio, Turab Mohammed, Leidy Lismeris Isenalumhe, Frederick L. Locke, Michael D. Jain, Bijal D. Shah

Blood (2023) 142 (Supplement 1): 6904.

https://doi.org/10.1182/blood-2023-190973

Published: 2023

Journal Articles

Baseline CRP and Ferritin Identify Patients at High Risk of Poor Outcomes after Axicabtagene Ciloleucel Despite Corticosteroid Prophylaxis

Blood (2022) 140 (Supplement 1): 4678–4680.

https://doi.org/10.1182/blood-2022-171084

Published: 2022

Journal Articles

Primary Progression on Frontline Therapy for Diffuse Large B-Cell Lymphoma Is Associated with a Poor Outcome Despite Subsequent CD19 Targeted CAR T-Cell Therapy

Ariel Perez Perez, Grace Johnson, Kedar Patel, Brian Arciola, Anthony Wood, Christina A Bachmeier, Julio C. Chavez, Bijal D. Shah, Farhad Khimani, Taiga Nishihori, Aleksandr Lazaryan, Marco L. Davila, Rahul Mhaskar, Frederick L. Locke, Sameh Gaballa, Michael D. Jain

Blood (2021) 138 (Supplement 1): 3855.

https://doi.org/10.1182/blood-2021-150735

Published: 2021

Journal Articles

Factors Affecting Lymphocyte Collection Efficiency and Manufactured Product Specification during Leukapheresis for Diffuse Large B Cell Lymphoma Patients Treated with Commercial Tisagenlecleucel

Ariel Perez Perez, MD, Christina A Bachmeier, PharmD, Renee Smilee, Albert J Ribickas, Aleksandr Lazaryan, MDPhDMPH, Julio C. Chavez, MD, Claudio Anasetti, MD, Bijal Shah, MD, Farhad Khimani, MBBS, Taiga Nishihori, MD, Marco L. Davila, MD PhD, Frederick L. Locke, MD, Michael D. Jain, MDPhD, Hien D. Liu, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-143336

Published: 2020

Journal Articles

The Lymphoma Tumor Microenvironment Influences Toxicity after CD19 CAR T Cell Therapy

Michael D. Jain, MD PhD, Rawan Faramand, MD, Verena Staedtke, MD PhD, Renyuan Bai, MBBS, Sae Bom Lee, Hiroshi Kotani, MD PhD, Kayla Reid, Kristen Spitler, Julio Chavez, Bijal Shah, MD, Christina A Bachmeier, PharmD, Marian Dam, ARNP, Brigett Brandjes, PA, Ricardo J Gonzalez, MD, John E Mullinax, MD PhD, Xuefeng Wang, PhD, Mohammad Hussaini, MD, Frederick L. Locke, MD, Marco L. Davila, MD PhD

Blood (2019) 134 (Supplement_1): 4105.

https://doi.org/10.1182/blood-2019-127305

Published: 2019

Journal Articles

Tumor Inflammation and Myeloid Derived Suppressor Cells Reduce the Efficacy of CD19 CAR T Cell Therapy in Lymphoma

Michael D. Jain, MD PhD, Hua Zhao, Reginald Atkins, Meghan A Menges, Crystal R Pope, Rawan Faramand, MD, Sae Bom Lee, Justin C. Boucher, PhD, Hiroshi Kotani, MD PhD, Christina A Bachmeier, PharmD, Julio Chavez, Bijal Shah, MD, Mohammad Hussaini, MD, Ricardo J Gonzalez, MD, John E Mullinax, MD PhD, Marco L. Davila, MD PhD, Frederick L. Locke, MD

Blood (2019) 134 (Supplement_1): 2885.

https://doi.org/10.1182/blood-2019-131041

Published: 2019

Journal Articles

Fever Characteristics Associated with Toxicity and Outcome after Anti-CD19 CAR T-Cell Therapy for Aggressive Lymphoma

Hamza Hashmi, MD, Alicia Darwin, Christina A Bachmeier, PharmD, Julio Chavez, Bijal Shah, MD, Javier Pinilla Ibarz, MD PhD, Taiga Nishihori, MD, Farhad Khimani, MD, Aleksandr Lazaryan, MDPhDMPH, Hien D. Liu, MD, Marco L. Davila, MD PhD, Frederick L. Locke, MD, Michael D. Jain, MD PhD

Blood (2019) 134 (Supplement_1): 1612.

https://doi.org/10.1182/blood-2019-126148

Published: 2019

Journal Articles

The Use of Intravenous Immunoglobulin (IVIG) during Severe Neurotoxicity Among the Recipients of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Sepideh Mokhtari, MD, Justin M Asquith, MD, Christina A Bachmeier, PharmD, Michael D. Jain, MD PhD, Peter Forsyth, MD, Frederick L. Locke, MD, Youngchul Kim, PhD, Aleksandr Lazaryan, MD PhD MPH

Blood (2019) 134 (Supplement_1): 5627.

https://doi.org/10.1182/blood-2019-122343

Published: 2019

Journal Articles

Prediction of CAR T-Related Toxicities in R/R DLBCL Patients Treated with Axicabtagene Ciloleucel Using Point of Care Cytokine Measurements

Rawan Faramand, MD, Hiroshi Kotani, MD PhD, Dylan Morrissey, Bin Yu, Frederick L. Locke, MD, Michael D. Jain, MDPhD, Julio C. Chavez, MD, Xuefeng Wang, PhD, Asmita Mishra, MD, Christina A Bachmeier, PharmD, Renier J. Brentjens, MD PhD, Sarah Yoo, Jae H. Park, MD, Marco L. Davila, MD PhD

Blood (2018) 132 (Supplement 1): 95.

https://doi.org/10.1182/blood-2018-99-116539

Published: 2018

NARROW

Cladribine and Cyclophosphamide Lymphodepletion Prior to Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma

Poor Hematopoietic Reserve at the Time of CD19 CAR T-Cell Infusion Is Associated with Long Term B-Cell Aplasia

Impact of Sarcopenia and Subsequent Muscle Loss on Post-CAR T-Cell Outcomes in Relapsed/Refractory Large B-Cell Lymphoma

A Novel Composite Endpoint of Toxicity-Free, Progression-Free Survival (TPFS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Cladribine and Cyclophosphamide Lymphodepletion Prior to Brexucabtagene Autoleucel in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma

Baseline CRP and Ferritin Identify Patients at High Risk of Poor Outcomes after Axicabtagene Ciloleucel Despite Corticosteroid Prophylaxis

Primary Progression on Frontline Therapy for Diffuse Large B-Cell Lymphoma Is Associated with a Poor Outcome Despite Subsequent CD19 Targeted CAR T-Cell Therapy

Factors Affecting Lymphocyte Collection Efficiency and Manufactured Product Specification during Leukapheresis for Diffuse Large B Cell Lymphoma Patients Treated with Commercial Tisagenlecleucel

The Lymphoma Tumor Microenvironment Influences Toxicity after CD19 CAR T Cell Therapy

Tumor Inflammation and Myeloid Derived Suppressor Cells Reduce the Efficacy of CD19 CAR T Cell Therapy in Lymphoma

Fever Characteristics Associated with Toxicity and Outcome after Anti-CD19 CAR T-Cell Therapy for Aggressive Lymphoma

The Use of Intravenous Immunoglobulin (IVIG) during Severe Neurotoxicity Among the Recipients of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Prediction of CAR T-Related Toxicities in R/R DLBCL Patients Treated with Axicabtagene Ciloleucel Using Point of Care Cytokine Measurements

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only